Infliximab en infusión intravenosa rápida. Eficacia y complicaciones

Generini, 2004, Infliximab in spondyloarthrpathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations, Ann Rheum Dis, 63, 1664, 10.1136/ard.2003.012450 Demetter, 2005, Colon mucosa of patients both with spondyloarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163, Ann Rheum Dis, 64, 321, 10.1136/ard.2003.018382 Bell, 2000, Antibodies to tumour necrosis factor alpha as treatment for Crohn’s disease, Lancet, 355, 858, 10.1016/S0140-6736(99)00442-0 Van den Bosch, 2002, Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy, Arthritis Rheum, 46, 755, 10.1002/art.511 Yazdani-Biuki, 2005, Blockade of tumour necrosis factor α significantly alters the serum level of IgG and IgA rheumatoid factor in patients with rheumatoid arthritis, Ann Rheum Dis, 64, 1224, 10.1136/ard.2004.030262 Barrera, 2001, Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis, Ann Rheum Dis, 60, 660, 10.1136/ard.60.7.660 Kruithof, 2005, Histological evidence that infliximab tratments leads to downregulation of inflammation and tissue remodelling of the synovial membrana in spondylorthropathy, Ann Rheum Dis, 64, 529, 10.1136/ard.2003.018549 Van Oosterhout, 2005, Clinical efficacy of infliximab plus mehotrexate in DMARD naïve and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNFα and IL18 but not CXCL12, Ann Rheum Dis, 64, 537, 10.1136/ard.2004.024927 Keller, 2003, Cytokines in the seronegative spondylorthropathies and their modification by TNF blockade: a brief report and literature review, Ann Rheum Dis, 62, 1128, 10.1136/ard.2003.011023 Temekonidis, 2003, Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study, Ann Rheum Dis, 62, 1218, 10.1136/ard.2003.014258 Familian, 2005, Infliximab treatment reduces complement activation in patients with rheumatoid arthritis, Ann Rheum Dis, 64, 1003, 10.1136/ard.2004.029124 Akinson, 2001, C-reactive protein: a rheumatologist’s friends revisited, Arthritis Rheum, 44, 995, 10.1002/1529-0131(200105)44:5<995::AID-ANR177>3.0.CO;2-L Kruithof, 2005, Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodeling of the synovial membrane in spondyloarthrpathy, Ann Rheum Dis, 64, 529, 10.1136/ard.2003.018549 Elliot, 1993, Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha, Arthritis Rheum, 36, 1681, 10.1002/art.1780361206 Maini, 1999, Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group, Lancet, 354, 1932, 10.1016/S0140-6736(99)05246-0 Fitzcharles, 2002, The use of infliximab in academic rheumatology practice: an audit of early clinical experience, J Rheumatol, 29, 2525 Neven, 2005, Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice, Ann Rheum Dis, 64, 645, 10.1136/ard.2004.028597 Nikas, 2004, Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study, Ann Rheum Dis, 63, 102, 10.1136/ard.2003.006981 Van Vollenhoven, 2005, Feasibility of 1 hour infliximab infusions [carta], Ann Rheum Dis, 64, 654, 10.1136/ard.2003.017590 Bañuelos-Ramírez, 2003, Anticuerpos monoclonales anti-TNFα, más metotrexato en artritis reumatoide resistente, Rev Mex Reumat, 18, 281 Balcázar-Sánchez, 2005, Estudio comparativo de aplicación de infliximab en 2 horas vs 1/2 hora a 45 minutos, Rev Mex Reumat, 20, 69 Van Eijk, 2006, Safety and patient satisfaction of infliximab administration in an extramural setting supervised by a rheumatology specialist nurse, Ann Rheum Dis, 65, 276, 10.1136/ard.2005.036566